<DOC>
	<DOCNO>NCT00242931</DOCNO>
	<brief_summary>RATIONALE : Giving low dos chemotherapy , fludarabine , radiation therapy donor stem cell transplant help stop growth cancer cell . It also stop patient 's immune system reject donor 's stem cell . The donated stem cell may replace patient 's immune system help destroy remain cancer cell ( graft-versus-tumor effect ) . Sometimes transplanted cell donor also make immune response body 's normal cell . Giving cyclosporine mycophenolate mofetil transplant may stop happen . PURPOSE : This phase II trial study well give fludarabine together total-body irradiation work treat patient undergo donor stem cell transplant progressive metastatic prostate cancer respond previous hormone therapy .</brief_summary>
	<brief_title>Flu/TBI Treating Patients Not Responding Previous Hormone Therapy</brief_title>
	<detailed_description>OBJECTIVES : - Determine treatment-related mortality patient hormone-refractory , progressive metastatic prostate cancer treat nonmyeloablative conditioning comprise fludarabine total-body irradiation follow allogeneic hematopoietic stem cell transplantation . OUTLINE : - Nonmyeloablative conditioning regimen : Patients receive fludarabine IV day -4 -2 total-body irradiation ( TBI ) day 0 . - Allogeneic hematopoietic stem cell transplantation ( AHSCT ) : After TBI , patient undergo AHSCT day 0 . - Immunosuppression : Patients receive oral cyclosporine twice daily day -3 56 followed taper day 81 . Patients also receive oral mycophenolate mofetil twice daily day 0-27 ( patient relate donor ) OR three time daily day 0-29 twice daily day 30-149 follow additional tapering day 180 ( patient unrelated donor ) . PROJECTED ACCRUAL : A total 10 patient accrue study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis adenocarcinoma prostate Metastatic progressive disease Refractory hormonal therapy Prostatespecific antigen ( PSA ) &gt; 5 ng/mL Previously treat docetaxelbased regimen No CNS metastases PATIENT CHARACTERISTICS : Performance status Karnofsky 70100 % Life expectancy More 6 month Hematopoietic Not specify Hepatic Bilirubin &lt; 2 time upper limit normal ( ULN ) AST ALT &lt; 4 time ULN Renal Creatinine clearance &gt; 50 mL/min Cardiovascular LVEF &gt; 35 % No symptomatic congestive heart failure Pulmonary DLCO &gt; 40 % predict OR Total lung capacity FEV_1 &gt; 30 % predict Other HIV negative PRIOR CONCURRENT THERAPY : Chemotherapy See Disease Characteristics Endocrine therapy See Disease Characteristics PATIENT AND DONOR SELECTION CRITERIA 4.1 Patient 4.1.1 Males age 1875 . 4.1.2 Pathologically proven adenocarcinoma prostate metastasis progressive disease ( new metastatic lesion increase cancerrelated pain rise PSA define consensus criterion . ( A rise PSA define 2 measurement higher initial value . The second 3 measurement must least 7 day first ) . 4.1.3 Progressive disease despite hormonal management ( include antiandrogen withdrawal , 6 week bicalutamide , 4 week flutamide nilutamide ) 4.1.4 PSA &gt; 5 ng/mL 4.1.5 Serum testosterone level &lt; 50 ng/mL 4.1.6 Prior treatment docetaxelbased regimen . 4.1.7 Performance status : Karnofsky Performance Scale ( KPS ) 70100 % . ( Appendix III ) . 4.1.8 Signed inform patient consent . 4.2 Patient Exclusion criterion : 4.2.1 Expected survival le 6 month 4.2.2 Active central nervous system involvement spinal instability 4.2.3 Organ dysfunction : 4.2.3.1 Cardiac : Ejection fraction &lt; 35 % symptomatic congestive heart failure . 4.2.3.2 Pulmonary : DLCO &lt; 40 % predict either TLC FEV1 &lt; 30 % predict . 4.2.3.3 Liver dysfunction : serum total bilirubin &gt; 2x upper limit normal ( ULN ) either ALT AST &gt; 4x ULN 4.2.3.4 Renal dysfunction : creatinine clearance &lt; 50 ml/min 4.2.4 HIV seropositivity 4.2 Related Donor Inclusion criterion : 4.3.1 Age 1875 4.3.2 Related patient genotypically phenotypically HLAidentical . ( Appendix IV ) 4.3.3 Able give consent peripheral blood stem cell mobilization GCSF apheresis collection . Bone marrow donor eligible . 4.3 Unrelated Donor Inclusion criterion : 4.4.1 Age 1875 . 4.4.2 Unrelated donor prospectively : 4.4.2.1 Matched HLADRB1 DQB1 alleles high resolution typing AND 4.4.2.2 Matched serologically recognize HLAA B C antigens least five six HLAA B C allele define Appendix IV . 4.4.3 Able give consent peripheral blood stem cell mobilization GCSF apheresis collection . Bone marrow unrelated donor eligible . 4.4 Related Unrelated Donor Exclusion criterion : 4.5.1 Identical twin . 4.5.2 Any contraindication administration GCSF mobilization . 4.5.3 Serious medical psychological illness . 4.5.4 Prior malignancy within precede five year , exception nonmelanoma skin cancer . 4.5.5 HIV seropositivity . 4.5.6 The donor pregnant , positive serum ÃŸhCG lactating .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>recurrent prostate cancer</keyword>
	<keyword>stage IV prostate cancer</keyword>
</DOC>